Ternary Therapeutics 🇬🇧
London AI/physics-based molecular glue drug discovery
About Ternary Therapeutics
TernaryTx specializes in designing molecular glue therapeutics using an AI-driven platform that integrates machine learning and physics-based methods. Their technology includes tools for predicting protein interactions, assessing complex stability, and optimizing molecular glue candidates, enabling the identification of previously \"undruggable\" targets.
Ternary Therapeutics is a UK-based company founded in 2024, now around 12 people. It has raised $4.8M in disclosed funding. FundFinder classes it as AI & ML.
Founded by Andrew Potterton (Chief Technology Officer and Co-Founder; previously BenevolentAI, Celeris Therapeutics; UCL), Chris Tame (Founder and CEO; previously BenevolentAI, Celeris Therapeutics; University of Strathclyde).
Its investors also appear on FundFinder's most-active lists for Seed · DeepTech (80 funds), Seed · Climate & Sustainability (80 funds), Seed · Life Sciences (32 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Seed · €4.1m · Mar 2026
- UK Innovation & Science Seed Fund (UKI2S) — Evergreen, government-backed pre-seed+ fund managed by Future Planet Capital. · cheques up to £1.5M